Regulatory science develops reliable ways to assess the safety, effectiveness, and quality of products. Its practical work includes improving safety tests, clinical trial methods, and monitoring after products reach the market. The FDA’s “Advancing Regulatory Science” page explains this role.

In Japan, Dr. Mitsuru Uchiyama (内山充) proposed the concept in 1987. He was then deputy director of the National Institute of Hygienic Sciences, the predecessor of today’s National Institute of Health Sciences, and later became its director. His proposal emphasized evaluating scientific advances so they benefit society. This establishes his role in Japan, rather than proving he invented the English term worldwide.

The field applies to pharmaceuticals, vaccines, medical devices, food, cosmetics, tobacco, and veterinary products. Related work also supports chemical safety and environmental regulation. Its scope extends well beyond drug approval.

Major agencies actively supporting it include the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). They support research, collaboration, and training.

Science broadly builds knowledge through observation, experiments, and testing explanations. Regulatory science concentrates on evidence needed for regulatory decisions. For example, discovering how a drug works advances scientific understanding; validating a method to measure its risks supports regulatory evaluation. Both require rigorous methods. Together, they help useful discoveries reach people with better evidence about benefits and harms.

How many researchers work in this field? I could not verify a reliable worldwide total. Researchers contribute from universities, industry, and government, often under titles such as toxicologist, statistician, or clinical researcher. The previously cited 150 EMA consultation respondents included organizations and individuals; that figure is not a researcher count. FDA’s university research partnerships provide clearer evidence of sustained institutional commitment.

Further expansion looks likely, although its pace is uncertain. EMA and European national regulators launched a research platform in March 2025, while FDA continues supporting research and training. These initiatives suggest growing demand for methods that can evaluate new technologies reliably.

What Has Regulatory Science Achieved?

Regulatory science involves developing evaluation methods, checking their reliability, and establishing how regulators can use the results. Three examples show its practical impact.

  • AI-assisted clinical trials: In December 2025, the FDA qualified AIM-NASH, an AI tool that helps pathologists assess liver biopsies in clinical trials. Validation studies supported its qualification for a defined use, with pathologists responsible for final interpretation. It could make assessments more consistent and efficient.
  • Evidence leading to updated drug information: In Japan, a study using the MID-NET medical database identified an increased risk of low platelet counts associated with pegfilgrastim. The findings supported a 2020 revision to its prescribing precautions. This is a concrete example of patient data informing safety measures after approval.
  • New ways to predict toxicity: In June 2026, the FDA accepted a proposal for an AI-based liver toxicity model into its qualification process. The aim is to improve predictions of drug-related liver injury and reduce reliance on animal testing. This was an initial evaluation milestone; full qualification had not been established by that announcement.